{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=9", "query": { "condition": "DNA", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 3219, "total_pages": 322, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T17:20:59.696Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05087849", "title": "Intralesional HPV Vaccine for Condylomata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Human Papilloma Virus", "Warts", "Warts, Genital", "Condyloma", "Condylomata Acuminata" ], "interventions": [ { "name": "nonavalent human papillomavirus vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-04-15", "completion_date": "2024-07-01", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05087849" }, { "nct_id": "NCT01610414", "title": "Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "Herpes Zoster vaccine GSK1437173A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1877, "start_date": "2012-07-13", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 23, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01610414" }, { "nct_id": "NCT00001604", "title": "Genetic Linkage Studies of Stuttering", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stuttering" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute on Deafness and Other Communication Disorders (NIDCD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 3044, "start_date": "2003-07-22", "completion_date": "2019-06-24", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001604" }, { "nct_id": "NCT01484015", "title": "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Burkitt Lymphoma", "Adult Diffuse Large Cell Lymphoma", "Adult Diffuse Mixed Cell Lymphoma", "Adult Diffuse Small Cleaved Cell Lymphoma", "Adult Hodgkin Lymphoma", "Adult Immunoblastic Large Cell Lymphoma", "Adult Lymphoblastic Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Breast Cancer", "Chronic Eosinophilic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cutaneous T-cell Non-Hodgkin Lymphoma", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Malignant Testicular Germ Cell Tumor", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Multiple Myeloma", "Mycosis Fungoides/Sezary Syndrome", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neutropenia", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Epithelial Cancer", "Ovarian Germ Cell Tumor", "Plasma Cell Neoplasm", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Primary Myelofibrosis", "Prolymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "cefepime hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484015" }, { "nct_id": "NCT02532452", "title": "Third Party Viral Specific T-cells (VSTs)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Viral Infection", "Viral Reactivation", "Infection in an Immunocompromised Host" ], "interventions": [ { "name": "Viral Specific VST Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Days", "maximum_age": null, "sex": "ALL", "summary": "2 Days and older" }, "enrollment_count": 1000, "start_date": "2015-09-02", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 4, "location_summary": "Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio", "locations": [ { "city": "Akron", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532452" }, { "nct_id": "NCT05677048", "title": "Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gynecologic Cancer", "Ovary Cancer", "Pancreatic Cancer", "Breast Cancer", "Lynch Syndrome", "Hereditary Breast and Ovarian Cancer Syndrome", "Colon Cancer", "Endometrial Cancer", "Uterus Cancer" ], "interventions": [ { "name": "Free genetic testing and counseling group", "type": "BEHAVIORAL" }, { "name": "IGNITE-TX Group", "type": "BEHAVIORAL" }, { "name": "IGNITE-TX and free genetic testing and counseling group", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2023-04-14", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05677048" }, { "nct_id": "NCT00002759", "title": "Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Lymphoma", "Neutropenia", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "phenobarbital", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "1996-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002759" }, { "nct_id": "NCT00470405", "title": "Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Solid Tumor" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-05", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2011-04-18", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470405" }, { "nct_id": "NCT00004058", "title": "12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Precancerous/Nonmalignant Condition" ], "interventions": [ { "name": "tetradecanoylphorbol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-12", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2010-01-26", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004058" }, { "nct_id": "NCT00002026", "title": "Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukoplakia, Hairy", "HIV Infections" ], "interventions": [ { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-28T17:20:59.696Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002026" } ] }